Article

Bausch & Lomb plans to double size of R&D center

Bausch & Lomb announced it will nearly double the size of its main research and development (R&D) center in Rochester, NY. The new two-story, 75,000-square-foot glass-and-brick wing will house laboratories and offices. It also will allow room for a future 25,000-square-foot addition.

Bausch & Lomb announced it will nearly double the size of its main research and development (R&D) center in Rochester, NY. The new two-story, 75,000-square-foot glass-and-brick wing will house laboratories and offices. It also will allow room for a future 25,000-square-foot addition.

The $35 million project includes $25 million for new construction and $10 million for renovations, equipment, and machinery, the company said in a prepared statement. The company is projected to add as many as 200 research jobs over the next 2 years.

The expansion "demonstrates our commitment to continue to develop innovative products to help people see, and will facilitate our plans to increase our presence in the nearly $20 billion global eye-health market," said Praveen Tyle, PhD, senior vice president and chief scientific officer of Bausch & Lomb.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.